Delivery Order SPE2DB22D3010-SPE2DB25FP2GR
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Zepbound 5 mg/0.5 mL pen injectors with a ceiling value of $6,706.07. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which carries a $999,999,999.00 prime vendor agreement through December 2026. The product will be performed at...
- The Defense Logistics Agency awarded a $4.5K delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Zepbound 12.5 mg/0.5 mL pen injectors, with a completion date of July 29, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $1 billion through December 2026. The place of performance is located in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 12, 2025, for the supply of Zepbound 5 mg/0.5 mL pen injectors with a ceiling value of $8,203.07 under a firm fixed price arrangement. The delivery order, which is non-set-aside and competitively awarded, is scheduled for completion by May 13, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $4,273.44 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Zepbound 10 mg/0.5 mL pen injectors with an ultimate completion date of August 18, 2025. This is a non-set-aside competitive award leveraging AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle that runs through December 2026....
- The Defense Logistics Agency awarded a delivery order valued at $5,237.35 to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Zepbound 5 mg/0.5 mL pen injectors. This competitive, firm fixed-price delivery order is scheduled for completion by September 10, 2025, with performance taking place at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Zepbound 5 mg/0.5 ml pen injectors, with a ceiling value of $46,729.78 under firm fixed pricing. This is a non-set-aside, competitively awarded contract with an ultimate completion date of August 14, 2025. The work will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under...
- The U.S. Department of Defense's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Zepbound 15 mg/0.5 mL pen injectors at a firm fixed price ceiling value of $3,579.97, with performance completion targeted for September 15, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with the Defense Logistics Agency Troop Support Medical,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Zepbound 5 mg/0.5 mL pen injectors valued at $3,349.68 under a firm fixed price contract. This non-set-aside award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. The pharmaceutical distributor will...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,622.22 to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Zepbound 5 mg/0.5 mL pen injectors. This is a firm fixed price, non-set-aside competitive award with a completion date of August 4, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $5,041.46 delivery order to AmerisourceBergen Drug Corp on June 18, 2025, for the supply of Zepbound 7.5 mg/0.5 ml pen injectors. This is a firm fixed price, non-set-aside contract with a completion date of June 20, 2025, and will be fulfilled at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at...
- SPE2DB22D3010Indefinite Delivery Contract
- SPE2DB22D3010-SPE2DB25FP2GRDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on April 24, 2025, for the supply of Zepbound 5 mg/0.5 mL pen injectors with a ceiling value of $1,143.87 and a completion date of April 25, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at approximately $1 billion through December 2026. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order falls within AmerisourceBergen's comprehensive pharmaceutical supply agreement with the Defense Logistics Agency, which supports military healthcare systems and other federal medical supply chain needs. As a major pharmaceutical distributor, AmerisourceBergen fulfills a critical role in providing brand-name and generic medications, specialty pharmaceuticals, vaccines, and medical supplies to the Department of Defense and related federal healthcare entities. The award of Zepbound, a diabetes medication, reflects the broader scope of the company's federal pharmaceutical procurement portfolio, which encompasses medications across multiple therapeutic domains to support military personnel and veteran healthcare programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 4/24/25 |